Amir Beirat

ORCID: 0000-0003-2222-8826
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatitis Pathology and Treatment
  • Pancreatic and Hepatic Oncology Research
  • Chronic Lymphocytic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Lung Cancer Diagnosis and Treatment
  • Global Cancer Incidence and Screening
  • Cancer Immunotherapy and Biomarkers
  • Gallbladder and Bile Duct Disorders
  • Cancer survivorship and care
  • Cancer Diagnosis and Treatment
  • Diabetes and associated disorders
  • Hemophilia Treatment and Research
  • Bipolar Disorder and Treatment
  • Neutropenia and Cancer Infections
  • Testicular diseases and treatments
  • Renal cell carcinoma treatment
  • Erythrocyte Function and Pathophysiology
  • Dietary Effects on Health
  • Cardiovascular Issues in Pregnancy
  • Stoma care and complications
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Chronic Disease Management Strategies
  • Acute Lymphoblastic Leukemia research
  • Palliative Care and End-of-Life Issues
  • Cancer, Hypoxia, and Metabolism

Indiana University School of Medicine
2023-2024

Indiana University
2023-2024

University School
2024

King Hussein Cancer Center
2024

Ball Memorial Hospital
2021-2023

Indiana University Health
2021-2022

University of Jordan
2021

Abstract Background Lymph node ratio (LNR) may offer superior prognostic stratification in colorectal adenocarcinoma compared with N stage. However, candidate cutoff ratios require validation. We aimed to study the significance of LNR and its optimal ratio. Methods reviewed pathology records all patients stage III who were managed at King Hussein Cancer Center between January 2014 December 2019. then studied clinical characteristics patients, correlates lymph count, positive nodes, value...

10.1186/s13000-024-01449-6 article EN cc-by Diagnostic Pathology 2024-02-28

The authors report the first case of stage 4 cytokine release syndrome (CRS) (graded by National Cancer Institute Common Terminology Criteria for Adverse Effects scale) involving a patient with advanced metastatic melanoma who was treated combination two monoclonal antibodies, nivolumab (anti-programmed cell death receptor 1 inhibitor [PD-1]) and ipilimumab (a cytotoxic T lymphocyte-associated antigen [CTLA-4]) after her dose both. initially methylprednisolone tocilizumab but refractory to...

10.1159/000525173 article EN cc-by-nc Case Reports in Oncology 2022-06-27

The role of cytoreductive nephrectomy has become unclear since the introduction immunotherapy which is now backbone treatment for metastatic renal cell carcinoma. Different combinations are used based on prognosis. Achieving a complete response would be ideal and includes radiographic disappearance lesions. However, there have been few reported cases pathological with persistent evidence cancer. authors report case despite residual disease in patient carcinoma treated pembrolizumab axitinib....

10.1159/000529124 article EN cc-by-nc Case Reports in Oncology 2023-02-02

Acquired factor X deficiency is a rare diagnosis, especially without the association of other co-existing conditions such as amyloidosis. The authors report case 34-year-old male with severe frank hematuria found to have markedly prolonged prothrombin time and activated partial thromboplastin time. A mixing study showed correction utilizing normal plasma coagulation panel testing revealed decreased activity. patient was treated multiple blood transfusions, fresh frozen plasma, high-dose...

10.3390/hematolrep15020032 article EN cc-by Hematology Reports 2023-05-15

We aimed to investigate the effect of dosage reduction four hypoglycemic multidrug regimens on incidences acute glycemic complications in people with type 2 diabetes who fast during Ramaḍān.We conducted an open-label, parallel-group, randomized controlled trial at a tertiary care center Amman, Jordan. recruited adults expressed intention Ramaḍān and were adherent one regimens-namely: metformin glimepiride; vildagliptin; insulin glargine U100; or, metformin, U100, human regular insulin....

10.3389/fendo.2021.613826 article EN cc-by Frontiers in Endocrinology 2021-07-07

Hereditary platelet delta (δ)-storage pool deficiency is a rare condition in which there are fewer dense granules platelets disrupting primary hemostasis. It can cause mild-moderate bleeding tendency with normal coagulation studies; hence, it an underdiagnosed diagnostic challenge. The authors present three patients hereditary who had heavy menstrual bleeding, excessive following surgery, mucocutaneous and score greater than or equal to 6. These cases reveal the susceptibility of...

10.3390/hematolrep15030041 article EN cc-by Hematology Reports 2023-06-29

Tumor lysis syndrome (TLS) is an oncologic emergency characterized by the destruction of tumor cells leading to influx large amounts uric acid, potassium, and phosphorus into systemic circulation. It most often occurs after initiation cytotoxic therapy in high-grade lymphomas leukemias; however, rarely it may occur spontaneously. The authors report a case spontaneous causing electrolyte abnormalities acute kidney injury patient with subsequently diagnosed chronic lymphocytic leukemia burden....

10.1159/000524198 article EN cc-by-nc Case Reports in Oncology 2022-04-22

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5359 article EN 2023-05-01

e22503 Background: The US Preventive Services Task Force reported 14.2 million Americans qualify for lung cancer screening. As per the Lung Cancer Screening Trial, using low dose computed tomography (LDCT) screening demonstrated a 20% reduction in cancer-related deaths. Despite that, 2022 State of Report from American Association indicates that only 5.8% eligible patients U.S. undergo Indiana, where this study was conducted, is ranked 46/50 and 44/50 number smokers incidence cancer,...

10.1200/jco.2023.41.16_suppl.e22503 article EN Journal of Clinical Oncology 2023-06-01

306 Background: Despite the critical importance of lung cancer screening (LCS), its uptake remains dismally low, with only 5.8% eligible individuals undergoing screening. To harness potential benefits LCS, there is an urgent need for shared decision making (SDM) between patients and primary care physicians (PCPs), who often serve as initial point contact. Recognizing this need, Centers Medicare Medicaid Services endorse LCS through low-dose computed tomography (LDCT) following SDM. This...

10.1200/op.2023.19.11_suppl.306 article EN JCO Oncology Practice 2023-10-26

121 Background: Lung cancer (LC) is the leading cause of cancer-related death for women in United States (US). It surpasses combined mortality rate breast, cervical and ovarian cancers. Early detection LC at stage I increases 5-year survival to 80%. Cancer Screening (LCS) an effective tool early detection. However, while 78% over 50 US undergo Breast (BCS), only 6% eligible receive LCS. Methods: This a retrospective study all diagnosed with primary presenting Indiana University Simon...

10.1200/op.2023.19.11_suppl.121 article EN JCO Oncology Practice 2023-10-26

Introduction: Multisystem Inflammatory Syndrome was first described in children (MIS-C) after COVID-19 infection, it is characterized by gastrointestinal symptoms, shock, fevers, elevated inflammatory markers, and systolic dysfunction. A few similar presentations have also been reported young adults designated as Adult type (MIS-A). Often, due to multi-organ involvement, extensive testing undertaken with no yield of a clear etiological factor. We present case 23-year-old male who admitted...

10.1097/01.ccm.0000907620.01390.03 article EN Critical Care Medicine 2022-12-15

Coronavirus disease 2019 (COVID-19) has caused significant morbidity and mortality in a vast majority of the patient population, especially those with malignancies. Chronic lymphocytic leukemia (CLL) is most common adults often an indolent disease. High white blood cell counts greater than 120 k/cumm chronic may be implicated cases COVID-19. Hyperleukocytosis leads to falsely elevated potassium levels due fragility. Pseudohyperkalemia occurs when present movement out cells during or after...

10.7759/cureus.20826 article EN Cureus 2021-12-30
Coming Soon ...